| Hans-Günter Meyer-Thompson | Verschiedenes
Making the investment case: Cost-effectiveness evidence for harm reduction
Making the investment case: Cost-effectiveness evidence for harm reduction
In an era of shrinking international funding to address HIV, hepatitis C (HCV)
and tuberculosis (TB), and competing priorities for domestic investment in health programmes, there is growing emphasis on ensuring value for money, efficient allocation of resources, and cost-effectiveness. (HRI – Harm Reduction International, 2020)
http://fileserver.idpc.net/library/HRI_cost_effectiveness_briefing.pdf